Literature DB >> 21181020

[HTLV-1 associated myelopathy: clinical and epidemiological profile in a 10-year case series study].

Ana Paula Silva Champs1, Valéria Maria de Azeredo Passos, Sandhi Maria Barreto, Luiz Sergio Vaz, João Gabriel Ramos Ribas.   

Abstract

INTRODUCTION: Human T cell lymphotropic virus type 1 (HTLV-I) myelopathy (HAM/TSP) is a progressive disabling disorder. This work aimed to analyze clinical features and epidemiology in a sample of HAM/TSP.
METHODS: All HTLV-1 infected patients with diagnostic criteria for HAM/TSP, consecutively admitted to the Sarah Hospital from 1998 to 2007, were included in the study.
RESULTS: 206 patients (67% females; mean age: 53.8 years-old) were diagnosed with HAM/TSP. The mean time of evolution was 9.0 years. The most common neurological symptoms were chronic progressive spastic paraparesis, spasticity, pain, neurogenic bladder and neurogenic bowel. The neurological findings were hyperreflexia, Babinsky, Hoffman and peripheral neuropathy. Pain, spasticity and spinal cord atrophy, observed in MRI, were associated with time of disease (p<0.05).
CONCLUSIONS: HAM/TSP is a very disabling disorder, in which pain is reported early, while spasticity and thoracic spinal cord atrophy appear in a later phase of the disease. Cases of HAM/TSP exist with a probable vertical viral transmission.

Entities:  

Mesh:

Year:  2010        PMID: 21181020     DOI: 10.1590/s0037-86822010000600013

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  7 in total

1.  Incomplete myelopathy and human T cell lymphotropic virus type-1 (HTLV-1).

Authors:  Roberta Vilela Lopes Koyama; Gilberto Toshimitsu Yoshikawa; Satomi Fujihara; George Alberto da Silva Dias; Rodrigo Rodrigues Virgolino; Anderson Raiol Rodrigues; Rita Medeiros; Juarez Antônio Simões Quaresma; Hellen Thaís Fuzii
Journal:  J Neurovirol       Date:  2018-10-05       Impact factor: 2.643

2.  Therapeutic effects of virtual reality video gaming on functional mobility, balance, and gait speed in individuals with tropical spastic paraparesis: A randomized crossover clinical trial.

Authors:  Erika Pedreira da Fonseca; Katia Nunes Sá; Rebeca Freitas Reis Nunes; Camille Rosa de Jesus Souza; Mayra Castro de Matos Sousa; Elen Beatriz Pinto
Journal:  Rev Soc Bras Med Trop       Date:  2021-01-29       Impact factor: 1.581

3.  Brazilian Protocol for Sexually Transmitted Infections 2020: human T-cell lymphotropic virus (HTLV) infection.

Authors:  Carolina Rosadas; Carlos Brites; Denise Arakaki-Sanchez; Jorge Casseb; Ricardo Ishak
Journal:  Rev Soc Bras Med Trop       Date:  2021-05-17       Impact factor: 1.581

4.  Bladder dysfunction in human T cell lymphotropic virus infection: A prospective cohort study.

Authors:  José Abraão Carneiro Neto; Cássius José Vitor de Oliveira; Sheila Nunes Ferraz; Mariele Guerra; Lívia Alves Oliveira; Lúcia Passos; Edgar M Carvalho; Paulo Novis Rocha
Journal:  PLoS Negl Trop Dis       Date:  2022-01-14

5.  Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM/TSP Patients: Comparison of HTLV-I Proviral Load in HAM/TSP Patients.

Authors:  Rosita Vakili; Faezeh Sabet; Sanaz Aahmadi; Reza Boostani; Houshang Rafatpanah; Ali Shamsian; S A Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

6.  Spinal cord hypometabolism associated with infection by human T-cell lymphotropic virus type 1(HTLV-1).

Authors:  Luiz C F Romanelli; Débora M Miranda; Anna B F Carneiro-Proietti; Marcelo Mamede; Herika M M Vasconcelos; Marina L Martins; Anísia S D Ferreira; Daniela V F Rosa; Jonas J Paula; Marco A Romano-Silva; Rodrigo Nicolato
Journal:  PLoS Negl Trop Dis       Date:  2018-08-27

7.  Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder.

Authors:  Jose Abraão Carneiro Neto; Silvane Braga Santos; Gloria Orge Orge; Davi Tanajura; Lucia Passos; Cassius José Oliveira; Rosana Andrade; Cláudio Galeno de Melo; Ubirajara Barroso; Edgar M Carvalho
Journal:  Braz J Infect Dis       Date:  2018-02-17       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.